Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00038142
Other study ID # ID97-198
Secondary ID NCI-2012-01285
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 1997
Est. completion date March 2016

Study information

Verified date January 2020
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objectives:

1. To determine if dose intensive Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) with or without ImmTherTM can improve the 2-year disease-free survival seen with standard VAC therapy.

2. To evaluate the feasibility and describe the toxicity associated with VACdxr.

3. To evaluate the feasibility and describe the toxicity of administering ImmTherTM on a weekly basis for 50- 52 weeks.

4. To determine which therapy (VACdxr+ or VACdxr-) is worthy of further evaluation.


Description:

Patients will be assigned at random (as by the toss of a coin) to receive 1 of 2 treatments.

Arm A: VACdxr will be given over 2 days through a needle in a vein. On day 1, vincristine will be given over 15 minutes, and doxorubicin will be given over 30 minutes.

Dexrazoxane will be given 30 minutes before doxorubicin; this drug protects the heart from damage by doxorubicin. Cyclophosphamide will be given once a day on days 1 and 2. This will make up 1 cycle of VACdxr treatment; the cycle will be repeated every 3 weeks for up to 6 cycles.

To prevent some side effects of VACdxr, the drugs Mesna and Neupogen/or Neulasta will also be given. Mesna helps prevent bladder damage. Neupogen is a growth factor that stimulates the body to make more white blood cells. Neulasta is a growth factor related to Neupogen.

After cycle 3, surgery may be done to remove any tumor that remains. The principal investigator will also decide whether radiation treatment should be done. If so, patients will receive radiation therapy.

Starting 1 month after all treatment is done, patients will receive ImmTher. ImmTher stimulates the body's white blood cells to attack and kill tumor cells. The drug will be given through a needle in a vein over 1 hour, every week for 1 year.

Arm B: Patients will be treated the same as patients in Arm A, except that they will not receive ImmTher.

Patients may have to stay in the hospital during VACdxr treatment and after surgery. Patients will receive ImmTher in the outpatient clinic.

Before treatment starts, patients will have a complete exam including blood and urine tests and an EKG and ECHO or multiple gated acquisition scan (MUGA) (heart function tests). X-rays and CT, MRI, bone marrow aspiration, and bone scans will be done. Women will have a pregnancy test.

After each treatment with drugs, after surgery, and after radiation treatment, patients will have checkups. These will include blood and urine tests and sometimes x-rays.

After cycle 3 of VACdxr, patients will have chest x-ray and x-ray of primary tumor. CT chest, MRI, bone marrow aspiration and bone scans will be done after 3 cycles as indicated. These tests will be done to record and measure tumors.

After treatment stops, patients will return for checkups every 3 months for 2 years.

This is an investigational study. ImmTher is an investigational agent. All other study drugs are approved by the U.S. Food and Drug Administration. As many as 104 patients will take part in the study; about 95 of these will be treated at M.D. Anderson.


Recruitment information / eligibility

Status Terminated
Enrollment 46
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender All
Age group 3 Years to 60 Years
Eligibility Inclusion Criteria:

- High risk Ewing's Family of tumors (metastatic disease at diagnosis, humerus, femur or trunk primary, bulky primary (greater than 8 cm)), or LDH greater or equal to 900 IU/ml prior to biopsy.

- No prior chemotherapy.

- Written informed consent

- Normal cardiac function (ejection fraction greater or equal to 50%).

- Males and non pregnant females.

- Biologic age 3-60 years old.

- Adequate bone marrow function (defined as an absolute peripheral granulocyte count of>500/mm3, platelet count of >75,000/mm3, and hemoglobin >8g/dl with transfusion if required).

- Adequate renal function defined as blood urea nitrogen (BUN) <30mg% and serum creatinine <1.5 x normal for age or creatinine clearance >70.

- Patients of child bearing potential must agree to use an effective method of contraception.

- Normal hepatic function (bilirubin <1.5mg/dl, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) <3x normal).

Exclusion Criteria: N/A

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vincristine
2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
Doxorubicin
90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6.
Cyclophosphamide
2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6.
Dexrazoxane
900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
Biological:
ImmTher
900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2-year Disease-free Survival (DFS): Effect of Treatment With Combination Drugs in VACdxr Given in High Doses With or Without ImmTher to Help Participants With Ewing's Sarcoma Live Longer DFS defined as survival of participants to two years post study entry without relapse. 2 years
See also
  Status Clinical Trial Phase
Withdrawn NCT01734863 - Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Phase 3
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT02736565 - Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT00563680 - QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Phase 2
Completed NCT00987636 - Study in Localized and Disseminated Ewing Sarcoma Phase 3
Completed NCT02890758 - Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Phase 1
Completed NCT01583543 - Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Phase 2
Terminated NCT01313884 - Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma Phase 2
Completed NCT01696669 - Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Phase 2
Completed NCT00004853 - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Phase 1
Terminated NCT00568464 - Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) Phase 2
Completed NCT00001686 - Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed NCT00492141 - Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Phase 1/Phase 2
Active, not recruiting NCT00541411 - Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma N/A
Completed NCT02063022 - Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Phase 3
Completed NCT01598454 - Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides Phase 1
Recruiting NCT03442465 - Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Completed NCT02511132 - A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Phase 2
Completed NCT00923650 - Informed Consent in Pediatric Cancer Trials N/A
Completed NCT01962103 - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Phase 1/Phase 2